FORT LAUDERDALE, Fla.,
Nov. 18, 2015 /PRNewswire/
-- Vigilant Biosciences, Inc., a leading innovator and
developer of solutions that aid in the early detection and
intervention of cancer, announced today that it has selected
Cardinal Health, Inc., a leading healthcare services company, as
its third party logistics provider for its
OncAlert™Oral Cancer System.
Effective immediately, Cardinal Health will oversee execution,
monitoring and reporting of the company's supply chain logistics in
the United States and
international markets. This includes day-to-day support for a wide
range of functions, including inventory and order management,
shipping, accounts receivable, billings and collections, as well as
customer service, as it relates to order shipments.
Vigilant Biosciences' OncAlert Oral Cancer System includes
the OncAlert™ Oral Cancer Rapid Point of Care Test
("OncAlert POC Test") and the OncAlert™ Oral Cancer
CD44/Total Protein LAB Test ("OncAlert LAB Assay"). As previously
announced, the OncAlert™ LAB Assay was CE registered
in November 2015, and Vigilant
Biosciences expects to begin shipping the product during the first
quarter of 2016. The OncAlert POC Test is currently undergoing the
CE Mark registration process.
"Cardinal Health's expertise in third party logistics, its
global recognition, and presence in the Life Sciences space made
them our top choice for our fulfillment needs," said Matthew H.J. Kim, Founder, Chairman, and CEO of
Vigilant Biosciences, Inc. "Our company is poised for rapid growth
over the next 24 months, with the launch of our OncAlert Oral
Cancer System in international and domestic markets, and Cardinal
Health is the right partner to help us support that growth while
ensuring the best possible experience for our customers."
"Vigilant Biosciences is an innovator in the early detection of
cancer and Cardinal Health is excited to support their growth with
our 3PL services. We look forward to a strong partnership," said
Jennifer Fillman, Vice President and
General Manager of Specialty Services for Cardinal Health.
About the OncAlert Oral Cancer System
Both products in
Vigilant Biosciences' OncAlert Oral Cancer System are based on
patented technology that detects specific protein markers
associated with oral cancer, even prior to the observation of
visual or physical symptoms. The simple, oral rinse procedure is
easy to administer and non-invasive for the patient. The test can
benefit every adult, with particular emphasis on high-risk
populations (i.e., current and former tobacco users, those who
consume excessive alcohol, and people with human papillomavirus
(HPV-16)). The OncAlert Oral Cancer System is not currently
available for sale in the United
States.
About Cardinal Health
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE:
CAH) is a $103 billion health care
services company that improves the cost-effectiveness of health
care. Cardinal Health helps pharmacies, hospitals, ambulatory
surgery centers, clinical laboratories and physician offices focus
on patient care while reducing costs, enhancing efficiency and
improving quality. Cardinal Health is an essential link in the
health care supply chain, providing pharmaceuticals and medical
products and services to more than 100,000 locations each day and
is also the industry-leading direct-to-home medical supplies
distributor. The company is a leading manufacturer of medical and
surgical products, including gloves, surgical apparel and fluid
management products. In addition, the company operates the nation's
largest network of radiopharmacies that dispense products to aid in
the early diagnosis and treatment of disease. Ranked #26 on the
Fortune 500, Cardinal Health employs nearly 35,000 people
worldwide. More information about the company may be found at
www.cardinalhealth.com/pharma3pl and @CardinalHealth on
Twitter.
About Vigilant Biosciences, Inc.
Vigilant Biosciences
is a leading innovator and developer of solutions that aid
clinicians in the early detection and intervention of cancer. The
company's point-of-care and lab-based tests that comprise its
OncAlert™ Oral Cancer System provide noninvasive,
accurate, and cost-effective tools designed to enable aiding early
detection prior to visible symptoms. The OncAlert™ LAB
Assay was CE registered in November
2015. The OncAlert™ POC Test is currently
undergoing the CE Mark registration process and not yet available
for sale in any market at this time. For more information, visit
www.vigilantbiosciences.com.
Logo - http://photos.prnewswire.com/prnh/20141210/163560LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/vigilant-biosciences-selects-cardinal-health-as-global-third-party-logistics-provider-for-oncalert-oral-cancer-system-300180619.html
SOURCE Vigilant Biosciences, Inc.